

Kimberly Miller, PhD

602-555-5343

www.linkedin.com/in/kimbmillier-phd

kimberlymiller@gmail.com

An accomplished leader with over ten years of management expertise in preclinical and clinical cancer research, education and training, with a creative and analytical approach for problem solving. Applies a mentoring style of management by coaching, inspiring and collaborating with associates to achieve the organization's goals and objectives. Identifies and validates molecularly guided therapies to personalize effective treatments for specific patient's needs.

CORE COMPETENCIES

- Project Management
- Strategic Analysis
- Team Leader / Builder
- Published Author and Speaker
- Strategic International Partnerships
- Lead Cross-Functional Teams
- Multilingual
- Extensive International Experience
- Excellent Communication Skills
- Assay Development

Lead: The Director of the Institute of Molecular Medicine (IMM) unexpectedly passed away. The lab needed an alternative Director and a \$1.3 million budget needed to be managed immediately. Assumed responsibilities of co-directing the lab, managing the research team and annual budget, and communicated with donors and funding organizations. RESULT: The lab was rescued from closure and the projects were successfully accomplished. An additional \$300,000 in grant funding was received over the next two years.

Adapt to Changing Priorities: A new senior research officer was recruited for the hospital and wanted to introduce genomic medicine to be implemented within routine diagnosis of childhood cancer. Assigned to lead the new project, I immediately demonstrated flexibility by shifting my research focus to address to new research priorities identified by the senior research officer. RESULT: Successful introduction of a new diagnostic tool in the hospital.

Initiate: Lab previously used only a genomic profiling approach to identify individual mutations in patients. While this approach is informative, it is not all-inclusive. I designed a protein profiling approach (proteomic) coupled with the genomic approach to provide a more comprehensive picture of individual molecular signatures in patients. This was accomplished by initiating collaborations with neighboring institutes. RESULT: Secured \$100,000 in research funding for this initiative.

Develop: Drug screening in leukemia is traditionally performed at regular room oxygen content, and on plastic surfaces. These conditions do not reflect the three-dimensional structure of the bone marrow or the low oxygen content where leukemic cells reside. Therefore, calculating the effective drug doses based on traditional screening methods is not accurate. Developed a new assay that incorporates the 3D structure and low oxygen content to test effective drug doses. RESULT: More accurate prediction of patients' response to drugs, which will eventually save thousands of dollars invested in assays that do not reflect the physiological conditions.

Inspire: Some lab trainees' performance was below average, which resulted in financial burden on the organization due to low productivity. Successfully coached associates through continuous guidance, instruction, regular meetings and mentorship. RESULT: Trainees became more productive, and achieved their goals and objectives. This reduced financial loss of the organization and helped shape the future of these valuable associates.

EDUCATION

PhD – Molecular Biology/Biochemistry/Cancer Biology –

University of Heidelberg / German Cancer Research Center (DKFZ) - Germany

M.S. – Cell Biology/Experimental Biology – Alexandria University, Faculty of Science - Egypt

B.Sc. – Zoology - Alexandria University, Faculty of Science - Egypt

Kimberly Miller, PhD

PROFESSIONAL HISTORY

Institute of Molecular Medicine at Phoenix Children's Hospital **2013 - Present**

Research Scientist (Translational Biomedicine) Phoenix, Arizona

Co-Director of the IMM lab (2015 – Present)

Under the leadership of Pediatric Oncologist Robert J. Arceci, MD, PhD (2013 – 2015)

- Built strategic relationships with leaders, clinicians, investigators in cross-functional teams.
- Led, supervised and trained a research team of clinical fellows, students and technicians.
- Managed annual laboratory budget and submitted project progress reports.
- Presented ongoing research with potential donors for philanthropic research funds.
- Successfully received research grants. Published papers as senior author.

University of Arizona College of Medicine – Phoenix **2013 - Present**

Associate Professor – Research Scholar Track

- Initiated / led collaborative research projects in the field of cellular response in drug resistance, phosphoproteomic signatures in acute myeloid leukemia and IGF-1R signaling.
- Member of the Graduate Committee of the Clinical Translational Sciences (CTS) Program.
- Mentored undergraduate / graduate students and trainees.

Cancer Center Karolinska – Karolinska Institutet (KI) **2010 - 2012**

Senior Researcher/Research Associate Professor

- Led research projects investigating targeting the Insulin-like growth factor-1 receptor (IGF-1R) in cancer and its role in stem cells.
- Collaborated with a Start-Up company for preclinical testing of an IGF-1R inhibitor.
- Supervised PhD and MS students at Karolinska Institutet and Stockholm University.

Alexandria University, Faculty of Science, Egypt **2002 – 2012**

Associate Professor (2007 – 2012)

Assistant Professor (2002 – 2007)

- Introduced / shared the Molecular Biology Division.
- Established the first Molecular Biology Research Lab.
- Initiated and led research projects in the field of natural products and IGF-1R signaling.

ADDITIONAL EXPERIENCE

Consultant: Participated in the development of an International Faculty Development Project about Responsible Conduct of Research (US National Academies); Strategic Planning Development of the Basic Science Sector (Egyptian Ministry of Higher Education and Research) • **Service and Professional Society Memberships:** Member of the Institutional Review Board (IRB) – Founder of the Biosafety Committee, Member of Research and Ethics Committee (Phoenix Children's Hospital) and the Academia-Industry Collaboration Committee (Alexandria University). • **Member:** American Society of Hematology (ASH), American Association for Cancer Research (AACR), International Union against Cancer (UICC) • **Research Grants:** Principal Investigator (PI) and co-investigator of grants (> \$1 M).

TECHNICAL QUALIFICATIONS

Biochemical, molecular and cell based assays, high-throughput drug screening, imaging, flow cytometry, immunohistochemistry, 3D cell culture, cell lines and primary human tumor samples, correlative studies in Phase I trials, genetically modified and xenograft mouse models, utilization of next generation sequencing to identify molecular targets in cancer | Microsoft Word, Excel, PowerPoint, Adobe Photoshop, Graph Pad Prism V 7.0, ModFit, Flow Jo